Drug Trial Radar · NCT06569056
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
579
Actual
Start
Sep 25, 2024
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
Conditions
- Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Interventions
HRS-8427Drug
Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Imipenem and Cilastatin SodiumDrug
Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
HRS-8427 placeboDrug
Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Imipenem and Cilastatin Sodium placeboDrug
Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.